[Using real-time polymerase chain reaction to quantitate bcr-abl mRNA]

Area of Science:

• Molecular Biology
• Oncology
• Biochemistry

Context:

• Minimal residual disease (MRD) in leukemia patients, defined as persistent tumor cells post-chemotherapy, is a primary cause of relapse.
• Accurate quantification of MRD is crucial for effective leukemia treatment and prognosis.
• The bcr-abl oncogene is a key marker in chronic myelocytic leukemia (CML).

Purpose:

• To establish a highly sensitive and reproducible real-time reverse transcription-polymerase chain reaction (RT-PCR) system for quantifying bcr-abl mRNA.
• To validate the system's performance using a leukemia cell line and patient samples.

Summary:

• A real-time RT-PCR system was developed and optimized using K562 cell line and plasmid standards.
• The method demonstrated high sensitivity (10 copies), stability (CV 3.21%), and reproducibility (CV 2.19%).
• Quantification of bcr-abl mRNA in 16 CML patients revealed a median level of 4.58x10^4 kb/microg RNA.

Impact:

• The developed real-time PCR assay provides a sensitive and specific tool for MRD detection and quantification in leukemia.
• This technology can guide therapeutic strategies and improve prognostic accuracy for CML patients.
• Enables precise monitoring of treatment response and early detection of relapse.